Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Borner

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
BMC Cancer|April 15, 2017
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)Bernhard C Pestalozzi, Christoph Tausch, Konstantin J Dedes, et al.
Oncology Research and Treatment|June 1, 2025
Guidelines of Onkopedia: What Is New?Magdalena K Scheck, Salah-Eddin Al-Batran, Markus Borner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancerStephen Chan, Max E Scheulen, Stephen Johnston, et al.
European Urology|April 16, 2013
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)Arnoud J Templeton, Valérie Dutoit, Richard Cathomas, et al.
BMC Cancer|October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Martin Bigler, Roger von Moos, et al.
European Journal of Cancer (Oxford, England : 1990)|September 2, 2020
European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatmentJeroen W G Derksen, Graham W Warren, Karin Jordan, et al.
Breast (Edinburgh, Scotland)|July 13, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancerEleonora Pagan, Monica Ruggeri, Nadia Bianco, et al.
Journal of Cancer Survivorship : Research and Practice|June 10, 2022
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and SwitzerlandKarin Ribi, Eleonora Pagan, Isabella Sala, et al.
Nature|September 17, 2010
Road will ruin SerengetiAndrew P Dobson, Markus Borner, Anthony R E Sinclair, et al.
Oncology Research and Treatment|October 25, 2020
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus PaperBernhard Wörmann, Carsten Bokemeyer, Thomas Burmeister, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
BMC Cancer|April 15, 2017
Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)Bernhard C Pestalozzi, Christoph Tausch, Konstantin J Dedes, et al.
Oncology Research and Treatment|June 1, 2025
Guidelines of Onkopedia: What Is New?Magdalena K Scheck, Salah-Eddin Al-Batran, Markus Borner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2005
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancerStephen Chan, Max E Scheulen, Stephen Johnston, et al.
European Urology|April 16, 2013
Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08)Arnoud J Templeton, Valérie Dutoit, Richard Cathomas, et al.
BMC Cancer|October 12, 2016
SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Martin Bigler, Roger von Moos, et al.
European Journal of Cancer (Oxford, England : 1990)|September 2, 2020
European practice patterns and barriers to smoking cessation after a cancer diagnosis in the setting of curative versus palliative cancer treatmentJeroen W G Derksen, Graham W Warren, Karin Jordan, et al.
Breast (Edinburgh, Scotland)|July 13, 2024
Factors influencing 5-year persistence to adjuvant endocrine therapy in young women with breast cancerEleonora Pagan, Monica Ruggeri, Nadia Bianco, et al.
Journal of Cancer Survivorship : Research and Practice|June 10, 2022
Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and SwitzerlandKarin Ribi, Eleonora Pagan, Isabella Sala, et al.
Nature|September 17, 2010
Road will ruin SerengetiAndrew P Dobson, Markus Borner, Anthony R E Sinclair, et al.
Oncology Research and Treatment|October 25, 2020
Dihydropyrimidine Dehydrogenase Testing prior to Treatment with 5-Fluorouracil, Capecitabine, and Tegafur: A Consensus PaperBernhard Wörmann, Carsten Bokemeyer, Thomas Burmeister, et al.
Pageof 5